Profile

Professor Uwe Siebert, MPH, MSc, ScD, MD

UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health

Contact Details

UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health

Bio

     Prof. Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health, Medical Decision Making and Health Technology Assessment (HTA), is the Chair of the Department of Public Health, Health Services Research and HTA at UMIT - University for Health Sciences, Medical Informatics and Technology in Austria and the Director of the Division for HTA in the ONCOTYROL – Center for Personalized Cancer Medicine in Austria. He is also Adjunct Professor of Health Policy and Management, and Epidemiology, at the Harvard T.H. Chan School of Public Health and Affiliated Researcher of the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston. He is the course director of the Harvard summer course on ‘Decision Analysis in Clinical Research’ and he has an adjunct teaching appointment at the School of Public Health and Epidemiology at the University of Munich.

     After medical school, he worked for several years as a physician in international public health projects in West-Africa, Brazil, and Germany. He then earned an MPH at the Munich School of Public Health, and completed an MSc in Epidemiology and a ScD in Health Policy and Management with a concentration in decision sciences at the Harvard School of Public Health. Before he started his faculty position at Harvard Medical School, he was the Director of the Bavarian Public Health Research and Coordinating Center at the University of Munich, Germany, and completed Visiting Scholarship at the Harvard Center for Risk Analysis.

     His research interests include applying evidence-based quantitative and translational methods from public health, epidemiology, artificial intelligence, comparative effectiveness research, health services & outcomes research, economic evaluation, modeling, and health data & decision science in the framework of health care policy advice and HTA as well as in the clinical context of routine health care, public health policies and patient guidance. His current substantive research focuses on cancer, infectious diseases (e.g., COVID-19, hepatitis C, HPV, HIV), cardiovascular disease, diabetes, neurological disorders, and others. His methodological research includes evaluations of public health interventions, prevention/screening, outbreak research, diagnostic imaging procedures, personalized medicine, non-pharmaceutical public health interventions, nature-based social prescribing, causal inference from “big” real world data and pragmatic trials, machine learning, decision modelling, and study designs controlling for treatment switching and noncompliance. He has been leading projects/work packages in several national and EU FP7 and H2020 projects (e.g., ELSA-GEN, BiomarCaRE, MedTecHTA, DEXHELPP, EUthyroid, FORECEE, MDS-RIGHT, RECETAS, EUREGIO-EFH, CIDS, OnCoVID). He teaches courses in decision-analytic modeling, HTA, economic evaluation, analysis of big data, machine learning, and causal inference at several universities and for industry in Europe, USA, South America, and Asia.

     Prof. Siebert is Past-President of the Society for Medical Decision Making (SMDM), a member of the Latin America Consortium Advisory Committee of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), member of the Oncology Advisory Council of the Federal Ministry of Health in Austria, member of the Advisory Board of the GÖG - National Austrian Public Health Institute, member of the Austrian Cochrane Collaboration Branch, and a member of several national and international Directors Boards (Austrian Society of Epidemiology, German Network of EbM; German Association for Medical Informatics, Biometry and Epidemiology). He has served as Vice President of SMDM, and member of the ISPOR Board of Directors, the Society for Medical Decision Making Board of Trustees; the Harvard Flagship Initiative in Comparative Effectiveness Research, the ‘National HTA Strategy’ Expert Group of the Austrian Federal Ministry of Health, the Advisory Board of the Ludwig Boltzmann Institute for HTA in Austria, the International Expert Committee Advising the Institute for Quality and Efficiency in Health Care (IQWiG) on the Methods for Economic Evaluations of Health Care Interventions, the Directors Board of the German Competence Network Heart Failure, and the Extended Board of Directors of the German Association of Health Economics.

     He is the Clinical Guideline Commissioner for the Association of the Scientific Medical Societies in Germany (AWMF), Authorized Expert in the COVID-19 Prognosis Consortium and the Scientific Platform Screening- and Monitoring Programs for COVID-19 of AGES - Austrian Agency for Health and Food Safety and GÖG advising the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection, Member of the Task Force for COVID-19 Vaccination Implementation of the State Government Tyrol, Chair of the Horizontal Initiative in Causal Inference of the German Society for Epidemiology (DGEpi), Chair of the Working Group “Effectiveness and Side Effects of Non-Pharmaceutical Interventions” of the Competence Network for Public Health for COVID-19, and Chair of the Working Groups ‘Health Economics’ and ‘Medical Decision Making’ of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS). He is Co-Chair of the ISPOR-SMDM Modeling Good Research Practices Task Force, Co-Chair of the ‘Issues in Methodology Section’ of the SMDM Policy Initiative, a Leadership Member of the ISPOR Personalized/Precision Medicine Special Interest Group, and member of the SMDM COVID-19 Modeling Special Committee.

     He has worked with several HTA Agencies (e.g., DAHTA@DIMDI/Germany, IQWiG/Germany, NICE/UK, ANVISA/Brazil, IATS/Brazil, CADTH/Canada, LBI-HTA/Austria, GÖG/Austria) and he advises public and government agencies, academic institutions and industry regarding the conduction of HTAs and their impact on policy and reimbursement decisions. He has authored more than 400 publications (H index > 50) including HTA reports, textbook chapters, scientific articles, policy briefs and editorials, and is Editor of the European Journal of Epidemiology, Associate Editor of Public Health Reviews as well as editorial board member of several scientific journals.